HempFusion Wellness Inc. (TSX: CBD.U) (OTC: CBDHF) (FWB: 8OO) Focuses on CBD Product Quality, International Expansion

June 8, 2021 08:15:01
  • HempFusion Wellness, Inc. is a health and wellness product marketer focused on hemp-derived cannabidiol (“CBD”) and probiotics
  • The company has been making in-roads in significant markets worldwide, using its probiotics as an entry point for potential future CBD product access to marketplaces currently hesitant to permit CBD
  • HempFusion recently announced that its Probulin probiotics products had been accepted for sale on Alibaba’s giant Tmall Global online marketplace throughout China, Hong Kong, Macau, and Taiwan, followed by conditional approval for selling some HempFusion CBD products there as well
Health and wellness supplement innovator HempFusion Wellness (TSX: CBD.U) (OTC: CBDHF) (FWB: 8OO) is advancing a visionary approach with a view to balancing people’s energy levels and general well-being by expanding its international distribution channels, demonstrating its compliance with regulatory standards for hemp-derived products worldwide while ferreting out access points for cannabidiol (“CBD”) in cannabis-wary outlets. HempFusion’s investment in meeting consumer health safety concerns has opened doors to major food and drug retail outlets and physician pipelines while many other CBD companies have searched for alternate entries into the competitive marketplace. The company’s HempFusion USA subsidiary, registered as HempFusion, Inc., provides consumers with a wide array of hemp-derived CBD products, including branded tinctures, capsules and products for sleep and stress. They also offer a full line of over-the-counter topicals designed to address, pain, eczema, acne and wound care.  Each of these OTC Drug listed products are formulated with a proprietary skin-nourishing and moisturizing base including Aloe vera, Shea butter, hemp extract derived omegas and CBD, botanical terpenes and other powerful botanicals.  The products are designed to serve performance athletes as well as the general public. HempFusion USA’s subsidiary Probulin Probiotics, LLC, produces a diverse group of scientifically formulated probiotic products that targets total gut health support, immune function support as well as probiotic extract based skin care for specific demographics to establish a competitive profile. The products provide help for consuming difficult-to-digest foods and for moisturizing and cleansing the skin, and some of them specifically are geared toward and women’s and children’s needs. The company’s products are sold in about 4,000 retail locations in all 50 U.S. states utilizing 45 brokers and sales representatives in the natural products industry and another 55 in the doctor/practitioner market, conventional food, drug, mass and convenience (“FDMC”) market and international markets, as well as the attention the company has received from its recent listings with the Toronto Securities Exchange (“TSX”) and the OTCQX markets. Probulin’s network for probiotics sales has proved useful for helping the company gain an entry point in marketplaces hesitant to consider CBD. For example, the company announce in March that Tmall Global, the world’s largest cross-border online marketplace with a reach of more than 750 million consumers in mainland China, Hong Kong, Macau and Taiwan, was permitting sales of Probulin’s Total Care Immune, Total Care, Daily Care, Women’s Health, Colon Support and My Little Bugs(TM) Total Care Probiotic For Kids (https://cnw.fm/wIyRh), and in April announced that Tmall has now conditionally approved, pending upcoming regulation changes in China,   HempFusion to sell its Acne Relief, Eczema Relief and Sports Pain Relief Creams, Pain Relief and Sports Pain Relief Balms, Pain Relief Gel and Wound Ointment products (https://cnw.fm/CaVMI). In the meantime, HempFusion continues to focus on other destinations within the Asian marketplace including Japan, Hong Kong and so on. HempFusion also sells its Probulin products in Mexico, South Korea and the United Arab Emirates, and Ireland with expectations of entering India and United Kingdom, where HempFusion’s CBD products may also reach consumer shelves. Probulin’s probiotics products are sold on Amazon, and although Amazon still does not allow CBD product sales HempFusion regards Probulin’s positioning as a potential quick-access point should Amazon change its policy regarding CBD sales. “COVID and continued lack of clarity from the FDA related to official regulatory guidance for CBD used in dietary supplements, foods and beverages has made 2020 a challenging year. However, these challenges have led to strategic changes, establishing the foundation for HempFusion to succeed in 2021 and beyond,” according to an April operational update by the company (https://cnw.fm/XrH05). For more information, visit the company’s website at www.HempFusion.com/corporate-information. NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://cnw.fm/CBDHF About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.